Bone remodeling is a balanced process between bone synthesis and degradation, maintaining homeostasis and a constant bone mass in adult life. Imbalance will lead to conditions such as osteoporosis or hyperostosis. Osteoblasts build bone, becoming embedded in bone matrix as mature osteocytes. Osteocytes have a role in sensing and translating mechanical loads into biochemical signals, regulating the differentiation and activity of osteoblasts residing at the bone surface through the secretion of Sclerostin (SOST), an inhibitor of WNT signaling. Excessive mechanical load can lead to activation of cellular stress responses altering cell behavior and differentiation. The unfolded protein response (UPR) is a shared pathway utilized by cells to cope with stress stimuli. We showed that in a transgenic mouse model, activation of the UPR in early differentiating osteocytes delays maturation, maintaining active bone synthesis. In addition, expression of SOST is delayed or suppressed; resulting in active WNT signaling and enhanced periosteal bone formation, and the combined outcome is generalized hyperostosis. A clear relationship between the activation of the unfolded protein response was established and the onset of hyperostosis that can be suppressed with a chemical chaperone, sodium 4-phenobutyrate (4-PBA). As the phenotype is highly consistent with craniodiaphyseal dysplasia (CDD; OMIM 122860), we propose activation of the UPR could be part of the disease mechanism for CDD patients as these patients are heterozygous for SOST mutations that impair protein folding and secretion. Thus, therapeutic agents ameliorating protein folding or the UPR can be considered as a potential therapeutic treatment. † These authors contributed equally.
Introduction
The bone mass is determined by the amount of bone accrued and a balanced remodeling process, involving the activities of osteoblasts, osteocytes and osteoclasts. Osteoblasts build bone while osteoclasts resorb bone, and osteocytes buried in bone are thought to regulate the differentiation and activity of both osteoblasts and osteoclasts (1, 2) . Perturbation of the activities of these cell types because of genetic alterations or gonadal failure results in reduced (osteoporosis) or increased bone mass (hyperostosis or osteopetrosis) (3) .
Transcription factors Runx2 and Osterix regulate the differentiation of progenitor cells along the osteogenic lineage to osteoblasts, transactivating genes for bone matrix proteins such as collagen I, osteocalcin and osteopontin (4) (5) (6) . Some osteoblasts become inactive bone-lining cells on the bone surface, while others are embedded within bone and differentiate to osteocytes with a distinct morphology and molecular signature (7) (8) (9) . Multiple stages of osteocyte differentiation can be described using morphology, molecular markers and location within bone (9) .
Osteocytes connect with one another and with osteoblasts at the bone surface via cellular processes, forming a canalicular network. They have emerged as a key regulator of bone remodelling in response to mechanical and hormonal cues. Early or differentiating osteocytes express Dmp1 that promotes hydroxyapatite formation and regulates the maturation of osteoyctes (10) . Osteocytes in Dmp1-/-mice have enlarged and round-shaped osteocytes with reduced numbers of cellular processes (10, 11) . Mature osteocytes produce sclerostin (SOST) which is received by osteoblasts at the bone surface via the osteocyte canalicular network, inhibiting WNT and BMP pathways, delaying differentiation of osteoprogenitors to osteoblasts and reducing the activity of osteoblasts. In mice, deletion of the Sost gene (12) or its enhancer region (13) result in high bone mass, supporting its role as a negative regulator of osteoblast function. Intercellular trafficking and transport of sclerostin to distant sites requires the canalicular network, because sclerostin accumulates around the osteocytic lacunae if the network is impaired, as in Mmp2-/-mice (14) . When the transport or secretion of sclerostin was disrupted, osteoblasts at the periosteum made excessive bone, resulting in hyperostosis and bones throughout the body became denser and wider than normal (14) . Sclerosteosis 1 (SOST1; OMIM 269500), hyperostosis corticalis generalisata or van Buchem disease (VBCH; OMIM 239100) and craniodiaphyseal dysplasia (CDD; OMIM 122860) are SOSTrelated sclerosing bone dysplasias. The common feature is a progressive overgrowth of craniofacial and tubular bones. Onset of hyperostosis is usually shortly after birth. CDD cases can be noticeable at birth to around 3 months of age (15, 16) . Mutations have been identified in SOST with some genotype/phenotype correlations. The mode of inheritance for SOST1 and VBCH is consistent with autosomal recessive, while CDD is autosomal dominant.
Recessive alleles from frameshift and nonsense mutations within the SOST gene have been identified in individuals with SOST1 (17) (18) (19) . Heterozygous carriers of SOST1 alleles have slightly higher bone mineral density than normal individuals but do not have a noticeable high bone mass phenotype (20) . A 52 kb homozygous deletion downstream of the SOST gene was most commonly identified in VBCH (21, 22) . A study in transgenic mice suggests this deleted region might contain a cisregulatory element that regulates SOST expression (23) .
Interestingly, CDD exhibits autosomal dominant inheritance. Two CDD cases with heterozygous SOST alleles for missense mutations (p. V21M and p. V21L) affecting the signal peptide cleavage site of the sclerostin have been identified (15, 16) . This suggests SOST mutations in CDD have a different, dominant-negative effect. In vitro study in transfected 293E cells showed that the signal peptide mutations impaired secretion of sclerostin, resulting in accumulation of the mutant protein within the endoplasmic reticulum (ER), which may activate ER stress (16) . Thus, activation of ER stress could be a contributing factor with a dominant effect. However, in the absence of relevant in vivo models, the role of ER stress in causing CDD has not been studied.
We have previously generated transgenic mice (13del-tg) that over-express a mutant form of collagen X in hypertrophic chondrocytes of the growth plate (24) . The mutation is analogous to a 13 bp deletion identified in the human COL10A1 gene, which causes a shift of the codon reading frame for the NC1 domain of the collagen X chain, resulting in Metaphyseal chondrodysplasia type Schmid (MCDS, OMIM 156500) (25) . The molecular consequence is abnormal folding of the mutant collagen chains: secretion is impaired and accumulation of the mutant proteins in the ER activates the unfolded protein response (UPR) (24) . We demonstrated that activation of ER stress signaling in hypertrophic chondrocytes did not induce cell death but disrupted the chondrocyte differentiation programme, causing dwarfism (24) .
Interestingly, apart from the growth plate changes (24), 13del-tg mice also exhibited hyperostosis, which is not a characteristic of MCDS. In this paper, we systematically analyzed the bone phenotype in 13del-tg mice which phenocopies that of human CDD caused by heterozygous SOST mutations that result in retention of SOST protein in the ER (16) . We asked whether ER stress signaling is the underlying cause of the hyperostosis in 13del-tg mice. Here, we show that the 13del transgene, in addition to its expression in hypertrophic chondrocytes, is ectopically expressed in osteocytes where it activates ER stress signaling. We found that the in vivo consequence of activating ER stress in osteocytes delays the maturation process and enhances bone production. This hyperostosis is specific to the effect of ER stress in osteocytes, not growth plate chondrocytes. The causative role of ER stress signaling is demonstrated by phenotypic rescue of hyperostosis by treatment with sodium 4-phenobutyrate (4-PBA), a chemical chaperone that assists protein folding. Our study implicates ER stress signaling as the underlying cause of CDD and suggests a possible treatment strategy using chemical chaperones.
Results

Progressive generalized hyperostosis in 13del-tg mice
Radiological analysis of 13del-tg mice showed a progressive generalized hyperostosis affecting endochondral and membranous bones. In wt mice, the radiological intensity of all bones is relatively constant at 5-10 weeks (Fig. 1A) . In 5-week-old 13del-tg mice, the bones of the appendicular and axial skeleton and the skull flat bones were markedly more radiologically intense than in wt mice (Fig. 1A) , suggesting an increase in bone mass. This hyperostosis increased progressively during early postnatal growth (Fig. 1A) . The bone phenotype was observed in four other independent transgenic founders with varying degrees of severity (Supplementary Material, Fig. S1 ), indicating it is not due to the effect of a specific transgene integration site.
Hyperostosis in 13del-tg mice is due to an increase in bone volume
Histological analysis showed that the thickness of the long and skull bones in 13del-tg mice appeared to be normal at birth. Bone thickening was first detectable at postnatal day 2 (P2; data not shown) after which it increased progressively with age (Fig.  1A) . Low magnification images of the whole tibia are shown in Figure 1B . All of the images captured for histological, immunohistochemical and in situ hybridization analyses are from the diaphysis region of the tibia unless otherwise stated. The cortical bone in the tibial diaphysis (Fig. 1C ) was markedly thicker, being doubled in some regions along the bone shaft of P10 and 4-week-old 13del-tg mice compared with wt (Fig. 1C) . Similar changes in bone thickening were observed for the calvarial bones in 13del-tg mice (Fig. 1C) . Consistent with the normal radiological observation, the thickness of long and flat bones in homozygous Col10a1 13del/13del (MCDS-ho) mice was similar to that in wt mice (Fig. 1C) . The MCDS mouse is generated by gene targeting of the 13del mutation into the endogenous mouse Col10a1 locus. Thus, the radiological changes in bone density mass are specific to 13del-tg mice that reflect an increase in the bone volume and is consistent with hyperostosis.
Skeletal changes in 13del-tg mice consistent with craniodiaphyseal dysplasia
To define more accurately the skeletal changes, we performed a microCT analysis on 6-month-old 13del-tg mice. We found that when all changes in all skeletal elements are considered, the 13del-tg phenotype is most consistent with CDD among the SOST-related sclerosing bone dysplasias, as follows. The nasal bone was broadened ( Fig. 2A ) with an enlarged mandible ( Fig.  2B ) that affected the alignment of the teeth between the upper and lower jaws (Fig. 2C ). Calvarial bones were significantly thickened ( Fig. 2D and E) and more pronounced at the suture sites (Fig. 2C) . In human CDD, excess bone formation manifests as facial distortion, which is usually described as 'leontiasis ossea' and progressively results in craniofacial foramina (26, 27) .
In the 13del-tg mice, thickening was more evident in the diaphysis than the metaphysis regions of tubular bones such as the tibia (Fig. 2F , H and I) and femur (Fig. 2G) . The tibial diaphyseal cortical thickness was significantly increased (Fig. 2J ) but the bone mineral density was reduced (Fig. 2K ). Other skeletal elements such as bones of the rib cage (Fig. 2L ) and the vertebral bodies of the spine (Fig. 2M) were also markedly thickened.
Poorly mineralized and porous bones in 13del-tg mice
Although radiological and histological analyses showed thicker bones, 3D backscattered electron-scanning electron microscopy (BSE-SEM) ( Fig. 3A) and quantitative topography-free BSE-SEM ( Fig. 3B ) revealed the cortical bones in 13del-tg mice to be porous and less compact compared with wt mice. In addition, the mineral density was uneven within cortical bones, in particular the osteoid nearer to the surfaces (Fig. 3B ) and regions surrounding the osteocytes. Under polarized light, the cortical bone from a 4-month-old 13del-tg showed irregular basophilic cement lines radiating from blood vessels that are normally not observed in wt mice (Fig. 3C ). Similar irregularity of bone cement lines was observed in human CDD biopsy (16) . These data suggest active bone deposition and possibly remodeling within the cortical regions of long bones. However, the bone formed is architecturally abnormal, is uneven and poorly mineralized, suggesting the tightly controlled balance between bone synthesis and degradation is impaired.
Bone resorption is not adversely affected in 13del-tg mice
Increased bone mass can also result from reduced bone resorption. The onset of bone phenotype is around postnatal day 2 (P2). We assessed the numbers of TRAP positive osteoclast in the tibial diaphysis region at P2 that showed no significant changes (Supplementary Material, Fig. S2A and B). Osteoclasts in tibial cortical and trabecular bones stained for TRAP activity showed normal intensity (Supplementary Material, Fig. S2C and D) and a normal morphology (Supplementary Material, Fig. S2E ). However, there appeared to be more residual TRAP activity in both the periosteum region as well as regions within the cortical bone, indicating bone remodeling and resorption are active (Supplementary Material, Fig. S2C ).
Resorption pit assay was performed to test whether 13del-tg bones are more difficult to be resorbed by osteoclasts. Bone slides prepared from wt and 13del-tg mice were digested with chicken osteoclasts for 24 h. The pits formed, evaluated by electron microscopy, showed no significant difference in pit area [wt: 811 6 107 (n ¼ 121); 13del-tg: 899 6 94 (n ¼ 187)], pit perimeter [wt: 183 6 17 (n ¼ 121); 13del-tg: 198 6 13 (n ¼ 187)] or pit volume [wt: 1741 6 247 (n ¼ 121); 13del-tg: 1701 6 200 (n ¼ 187)] between wt and 13del-tg bones. Together, these findings are consistent with a more active bone synthesis and remodeling process in 13del-tg mice, with an overall balance favoring bone accrual.
13del Col10a1 transgene is ectopically expressed in osteocytes
It has been reported that expression of the 13del transgene in hypertrophic chondrocyte of the growth plate leads to differentiation changes (24) . Thus, we hypothesized that this transgene might be expressed in bone cells, causing hyperostosis. Col10a1 is normally not expressed in bone as confirmed by in situ hybridization on the bones of P10 wt mice (Fig. 4A) . In 13del-tg mice, Col10a1 expression was detected in osteocytes, but not in the osteoblasts or bone lining cells (Fig. 4A) . Consistently, ColX13del proteins was detected in osteocytes of 13del-tg mice (Supplementary Material, Fig. S3F ). Similar expression of Col10a1 in osteocytes was observed for 13del-tg calvarial bone cells, but not cells in the periosteum or on bone surfaces. The ectopic expression of 13del was probably initiated in early postnatal life as 13del transcripts were not detected at birth, when osteoblasts predominate, but became evident by P2, coincident with the presence of more osteocytes, corresponding to the onset of hyperostosis at P2 (data not shown).
Hyperostosis in 13del-tg is not linked to the growth plate defects
The 13 bp deletion (13del) occurs in humans, causing MCDS (25) and 13del-tg mice present with changes in the growth plate consistent with MCDS (24). However, generalized hyperostosis is not a characteristic of patients with MCDS. We previously showed normal growth plates in transgenic mice (FColX-tg) overexpressing a wt Col10a1 transgene encoding a FLAG-epitope fused to the collagen X a-chain, under the same regulatory elements as the To test whether the bone phenotype was caused by the 13del mutation itself or by ectopic Col10a1 expression in osteocytes, we examined FColX-tg mice and found they did not exhibit generalized hyperostosis, and the bone density was similar to wt mice ( 13del/þ (MCDS-he) and MCDS-ho mice recapitulated the dwarfism phenotype characteristic of human MCDS patients (unpublished data) but generalized hyperostosis was not observed (Fig. 1A) . Taken together, the data suggest the hyperostosis is specific to ectopic expression of the 13 bp deletion in Col10a1 in osteocytes.
Expression of 13del transgene in osteocytes is directly linked to generalized hyperostosis
To substantiate the link between the expression of Col10a1-13del in osteocytes with hyperostosis, we exploited data showing that a shortened 5 to be significantly increased (n ¼ 3) (E). Thickening in tibia and fibula bones (F and H) that is more pronounce in the diaphysis (dp) than at the metaphysis (mp, white arrows) region. Similar bone thickening was observed in the femur (G). Transverse views of the tibial diaphysis (boxed regions) in (H) are shown in (I). The tibial cortical thickness was measured to be significantly increased in 13del-tg mice (n ¼ 3) (J) but the bone mineral density (BMD) was significantly reduced (n ¼ 3) (K). Rib cage (L) and the lumbar region of the vertebral column (M) were also markedly thickened.
The hypertrophic zone was with similar height to that of wt (Supplementary Material, Fig. S5A 
Active osteoblasts and osteocytes in 13del-tg mice bones
To understand how the 13del-tg causes hyperostosis, we analyzed the differentiation of osteoblasts and their maturation to osteocytes. In wt mice, spindle and cuboidal cells consistent with pre-osteoblasts and osteoblasts can be seen lining the bone surface in the periosteal region (Fig. 4B) . In 13del-tg mice, there are more layers of cells in this region, with many cells having the cuboidal morphology of 'active osteoblasts', which suggests active lateral bone growth in the diaphysis region (Fig.  4B) . Cells in the periosteal region express high level of Runx2 (Fig. 4C) , a master transcriptional factor that regulates osteoblast differentiation and bone matrix genes such as collagen I (Col1a1) (Fig. 4D ) and osteopontin (Opn) (Fig. 4F ). These genes are expressed in the bone lining cells of wt and at a higher level in 13del-tg mice. In addition, there were more cells expressing Runx2 in 13del-tg mice, suggesting either increased recruitment of osteoblastic progenitors to the endosteal bone surface or more active differentiation from osteoblast progenitor cells.
Col1a1 and Opn are normally down-regulated in the endosteum as osteoblasts become embedded in the bone matrix and differentiate to osteocytes. Interestingly, expression of these genes in 13del-tg osteocytes remained relatively high in both the endosteum and the cortical bone ( Fig. 4D and F ). The expression level and pattern of the mature osteoblast and osteocyte marker, osteocalcin (Ocn), was also changed in 13del-tg, being reduced in the endosteum compared with wt, but in contrast increased in the cells in the cortical bone (Fig. 4E) . Similar gene expression profiles were observed for osteoblasts and osteocytes in 13del-tg calvarial bones (Fig. 4G, H and I ). Together, these findings are consistent with altered maturation of osteoblasts or osteocytes and enhanced bone synthesis contributing to the generalized hyperostosis.
An immature osteocytic network in 13del-tg bone not expressing Sost
With bone growth, osteoblasts mature to osteocytes as they become embedded within the mineralized bone. In wt mice, osteocytes in cortical bones have the typical appearance of a mature osteocyte-slightly elongated with numerous cellular processes extending from the cell body ( Fig. 5A and B) . They orientate parallel to the bone surface and the cellular processes connect to form a canalicular osteocytic network extending to the bone surface. In 13del-tg mice, osteocytes embedded in the bone matrix are more cuboidal with spherical nuclei, looking like a 'young osteocyte' with fewer cellular processes, and there is no osteocytic network ( Fig. 5A and B ). They were also randomly distributed with no special orientation in the bone (Fig. 5A and B ). An assessment of the morphology/shape of osteocytes from wt and 13del-tg mice using a semi-quantifiable cell aspect ratio of the long/major (L) and short/minor (S) axis of the cells (Fig. 5C) , showed a lower L/S ratio for 13del-tg osteocytes (Fig. 5D) , indicating they are more cuboidal/rounded in shape.
Sost, a marker for mature osteocytes, is expressed in osteocytes of wt mice (Fig. 5E ) and Sclerostin protein is distributed throughout the cytoplasmic processes of the osteocytic network extending to the bone surface (Fig. 5F ). In contrast, low level of Sost is produced by the immature osteocytes in 13del-tg mice ( Fig. 5E and F) . In the few cells that are producing Sclerostin, it accumulates within the cell bodies in the absence of cytoplasmic processes (Fig. 5F ). These cells however have entered the osteocyte differentiation programme expressing Dmp1, an early osteocyte marker (Fig. 5G-I) . Interesting, there appears to be more Dmp1 retained within the osteocytes in 13del-tg by immunostaining (Fig. 5G-I) . Together, our findings indicate the presence of an immature osteocytic network in 13del-tg mice.
13del-tg expression activates ER stress signaling and de-regulates osteocyte differentiation and WNT signaling
To investigate the molecular changes leading to hyperostosis, we performed gene expression profiling using calvarial bone mRNA isolated from three wt and three 13del-tg littermates at P10. Each sample was hybridized to an Affymetrix Mouse 430.2 array. We set the expression threshold level at 100, and performed a scatter plot analysis of the expressed genes using the geWorkbench platform (28) showed a good correlation of the probeset signals between wt and 13del-tg ( Supplementary  Material, Fig. S7A ). Fold change analysis for detecting >50% change in gene expression showed 227 genes were upregulated by more than 1.5 fold in 13del-tg, and 902 genes downregulated by more than 33.3% (P 0.05). Col10a1 expression was highly upregulated in 13del-tg mice relative to the low level in wt mice (92-fold upregulated), consistent with the ectopic expression of the 13del transgene that was seen in immature osteocytes by in situ hybridization.
Gene Ontology (GO) Terms analysis showed 'Wnt signaling pathway' and 'Response to endoplasmic reticulum stress' are the two most significantly enriched GO Term for upregulated genes (Supplementary Material, Fig. S7B and Table S1 ), consistent with our previous finding that retention of 13del mutant proteins induce ER stress in chondrocytes (24) . Furthermore, consistent with upregulation of WNT targets Tcf7 and Ccnd1, we found that Wnt antagonist Sost, Dkk1 and Frzb were downregulated (Supplementary Material, Table S2 ). Ifitm5 (an osteoblastspecific marker) and Rankl were significantly upregulated (Supplementary Material, Table S2 ), while genes encoding for collagen I (Col1a1), osteopontin (Spp1), osteocalcin (Bglap) and dentin matrix protein 1 (Dmp1) also showed an upward trend (data not shown), consistent with higher bone synthesis and remodeling activities.
We validated some gene expression changes in UPR and WNT signaling using quantitative RT-PCR using RNA extracted from cortical bone at the diaphysis region (Supplementary Material, Fig. S7C and D) . The UPR target Chop is significantly upregulated, indicating the PERK-ATF4 axis is activated (Supplementary Material, Fig. S7C ). On the other hand, there was consistent downregulation of Sost expression and upregulation of WNT-targets Tcf1, Lef1, Opg and Rankl (Supplementary Material, Fig. S7D ). Collectively, our transcriptome data suggest that ER stress is induced in osteocytes, resulting in the deregulation of WNT signaling and bone formation.
Activation of ER stress in osteocytes expressing 13del transgene
Ectopic expression of the 13del transgene in osteocytes resulted in the production of 13del collagen X a-chains that cannot assemble into triple helix. As occurs in hypertrophic chondrocytes, the mutant collagen chains accumulated within the ER compartment ( Fig. 6A and B) , demonstrated by intracellular staining using an antibody specific for the 13del collagen X. Consistent with the enriched GO term 'Response to endoplasmic reticulum stress', our microarray analysis showed that genes encoding the ER stress markers Atf3, Ddit3 (Chop) and Hspa5 (BiP) were significantly upregulated 13del-tg calvaria bone (Supplementary Material, Table S2 ), indicating the induction of all the three arms of the UPR, indicating that intracellular accumulation of unfolded/unassembled proteins activated ER stress signaling. Immunostaining for several representative ER stress markers in 13del-tg osteocytes validated the transcriptome data. Atf4 and Atf3 (Fig. 6C and G) , targets of the PERK pathway which has roles in both the UPR and osteoblast differentiation, were upregulated, suggesting these ER stress-induced targets could also impact on osteocyte differentiation and network. Protein levels of BiP (Fig. 6E) and Xbp1s (Fig. 6F) , downstream targets of the ATF6 and IRE arms of the UPR were upregulated. Chop as a downstream target of the PERK pathway was also upregulated (Fig. 6D) . Co-localization of ColX-13del and Chop can be detected in some osteocytes in 13del-tg from consecutive sections where the same cells were presence in both sections (Supplementary Material, Fig. S8 ), providing further correlation between accumulation of mutant protein and ER stress activation. Similar observations of ER stress activation were made in 13del-SP-tg mice (Supplementary Material, Fig. S6D and E). These data indicate ER stress signaling is activated in the osteocytes of 13del-tg and 13del-SP-tg mice.
Activation of ER stress in osteocytes is directly correlated with hyperostosis
The ectopic expression of the 13del-transgene in osteocytes, localization of the 13del proteins inside the cells, and subsequent activation of ER stress signaling suggest that the primary defect in hyperostosis in 13del-tg mice is linked to ER stress. ER stress signaling induced by unfolded proteins can be alleviated in part by chemical chaperones such as TUDCA and sodium 4-phenylbutyrate (4-PBA) (29) (30) (31) . We therefore tested the effect of feeding 4-PBA from P2, analyzing the bones at P7. 4-PBA had no effect on the bones of wt mice ( Fig. 7A and B) but suppressed hyperostosis in their 13del-tg littermates (Fig. 7A  and B) . Thickness of the diaphyseal cortical bone in 13del-tg mice was significantly reduced when treated with 4-PBA (Fig.  7B) . The 13del-tg mice fed 4-PBA also showed reduced intracellular accumulation of 13del proteins assessed using the 13del specific antibody (Fig. 7C) , reduced expression of BiP (Fig. 7C) , and reduced number of BiP expressing cells in cortical bone (Fig. 7D) , consistent with an overall reduction in activation of ER stress.
Feeding 4-PBA after the onset of hyperostosis, from P5 to P14, led to a distinct morphological change from round to more elongated osteocytes with more extensive cellular processes and recovery of some canalicular structures in 13del-tg mice (Fig. 7E) . Using the cell aspect ratio as an assessment, there is a trend of improvement in the mean L/S ratio for 13del-tg osteocytes treatment group compare with the untreated group (Fig.  7F) . This trend can be better illustrated when cells are sub grouped into more rounded (L/S < 1.5) to more elongated (L/ S > 2) (Fig. 7G) . In addition, more cells with L/S ratio mean of wt (3.19) are observed in the treatment group (Fig. 7G) . Finally, fewer osteoblasts are found at the bone surface/periosteal (Fig.  7E) , consistent with the recovery of sclerostin expression ( Fig. 7H and I ) and function as a negative regulator in bone formation. Together, these findings suggest treatment with 4-PBA has a positive effect on osteocyte differentiation and function in 13del-tg mice.
Expression of a CDD related mutation in SOST activates ER stress in vitro
Two CDD signal peptide mutations (p.Val21Met and p.Val21Leu) in SOST resulted in the impaired secretion of sclerostin in transfected 293E cells (16) . However, whether this will lead to the activation of ER stress has not been addressed. To provide such an assessment and correlation to activation of ER stress in 13del-tg causing a CDD phenotype, we perform an in vitro expression of SOST with the p.Val21Leu mutation (Mut-SOST) (Fig. 8A ) in mouse MC3T3-E1 cells comparing with wild type (WT) SOST as control. Transient transfection of the expression constructs in MC3T3-E1 cells clearly showed an ectopic expression of the transgenes 24 h after cell transfection (Fig. 8B) . Activation of ER stress signaling with Mut-SOST transfection was evident with increased expression of BiP, Chop and Atf4 compared with WT-SOST transfection and untransfected MC3T3-E1 cells as controls (Fig. 8C) .
Discussion
Here, we use a transgenic mouse model expressing a shortened version of the Col10a1 gene, 13del-tg, to show activation of ER stress in osteocytes alters their maturation and bone homeostasis. The result is a generalized progressive hyperostosis most consistent with craniodiaphyseal dysplasia (CDD) (32) . Significantly, we provide evidence for a direct link between ER stress and CDD that can be modulated during early development with chemical chaperones through oral administration.
The 13del-tg mouse was generated to understand growth plate changes underlying MCDS (24) . Surprisingly, it showed hyperostosis which is not characteristic of MCDS. We provide evidence that ectopic expression of the 13del-tg transgene in osteocytes has a gain-of-function effect leading to hyperostosis. Increased bone phenotypes are known for several congenital skeletal disorders. As such the 13del-tg mouse could serve as an important model for human skeletal dysplasia.
Craniometaphyseal dysplasia (CMD) is an autosomal dominant disorder with mutations in ANKH. CMD is characterized by progressive thickening of craniofacial bones and flaring of the metaphyses of long bones (33) , bearing some resemblances to 13del-tg mice. However, it is accompanied by increased radiolucency of long bone, which is not consistent with generalized hyperosteosis in 13del-tg mice.
Both SOST1 and VBCH exhibit generalized hyperosteosis, but the recessive mode of inheritance for these diseases differs from that of 13del-tg mice. CDD has a dominant mode of inheritance with all the characteristics exhibited in 13del-tg mice. Furthermore, the two CDD signal peptide mutations (p. Val21Met and p. Val21Leu) in SOST resulted in the impaired secretion of sclerostin in transfected 293E cells (16) . Our study further showed that the signal peptide mutations could lead to activation of ER stress from an in vitro expression in mouse MC3T3-E1 cells. This is consistent with retention of 13del collagen X and activating of ER stress in osteocytes of 13del-tg mice. Similar signal peptide mutations in the collagen X gene resulted in impaired secretion in the cells causing MCDS (34) , although activation of ER stress was not assessed, but it is clear that activation of ER stress in hypertrophic chondrocytes is the molecular basis for MCDS (24) . Thus, we consider CDD as the most likely phenotype exhibited by 13del-tg mice. Given that the 13del-tg bone phenotype originates from a mutation in collagen X and not sclerostin, the common feature is ER retention of mutant proteins in osteocytes, and we propose this is sufficient to induce the generalized hyperostosis (Fig. 8D) .
We have several lines of evidence to support retention of mutant proteins and activation of ER stress in osteocytes as the primary cause. In 13del-tg mice, mutant collagen X is expressed by both hypertrophic chondrocytes and osteocytes. The transgene expression in osteocytes is the result of using a 1.7 kb fragment of the mouse Col10a1 promoter that appears to lack the regulatory elements to suppress expression in osteocytes. When the equivalent mutation was introduced by gene targeting with expression of the 13del collagen X restricted to hypertrophic chondrocytes, generalized hyperostosis was not observed. Furthermore, when we used a shortened Col10a1 5 0 regulatory sequence to generate 13delSP-tg mice, in which the transgene expression in hypertrophic chondrocytes was minimal but osteocyte expression was maintained, generalized hyperostosis still occurred. Lastly, we excluded over expression of and vehicle only (-PBA) were administered to 13del-tg mice daily from P5 to P14, and sacrificed at P15 for analysis. Histological analysis using the Bodian stain showing collagen X in osteocytes as a contributing factor because transgenic mice over-expressing wt collagen X were phenotypically 'normal'. From these findings, we conclude that hyperostosis is the result of expressing the mutant collagen X in osteocytes.
13del-expressing osteocytes are derived from osteoblasts on bone surfaces that become evident from P2, coincident with the formation of cortical bones and onset of hyperostosis. We defined these 13del-expressing cells as 'early differentiating osteocytes' or 'immature osteocytes', newly embedded in bone as they are expressing Dmp1, but without extensive cellular processes and not expressing Sost, both of which are characteristics of mature osteocytes. Thus, we propose the phenotypic outcome of CDD is similar to SOST1 and VBCH, each caused by a critical reduction of sclerostin level. In SOST1 and VBCH, this is due to loss-of-function mutations, and a critical reduction is seen in homozygous recessive patients. In CDD patients and in 13del-tg mice, the effect is dominant because activation of ER stress impairs maturation of osteocytes, but the end result is a critical reduction in sclerostin level, leading to perturbed regulation of osteoblast differentiation and proliferation.
A possible difference between CDD patients and those with SOST1 or VBCH is in osteocyte function and activity. Normally, osteocytes embedded in the bone matrix of cortical bone are aligned in the direction of mineralization, thus compact and parallel bone cement lines are observed (35) . In 13del-tg mice, the immature osteocytes actively synthesize bone matrix, resulting in irregular cement lines and prominent, irregular cement lines have been observed in bone biopsies from CDD patients (16) . Perturbation of the canalicular network may in part contribute to poor and uneven mineralization of bones in 13del-tg mice.
How the activation of ER stress interfere with osteocyte differentiation is not clear. In 13del-tg mice, the transgene was expressed by 'young osteocytes' as they became embedded into bone matrix. This would be the earliest stage when ER stress would be activated, and osteocytes nearest to the bone surfaces were positive for ER stress markers such as Xbp1 S and BiP.
These 'young osteocytes' do not yet express Sost, thus, the genes and signals involved in this interference would be those activated early in the ER stress response. The impact of the UPR activated by ER stress signaling in skeletal biology is evident from studies of osteochondrodysplasias, including multiple epiphyseal dysplasia, MCDS and osteogenesis imperfect (24, (36) (37) (38) . Of the three sensors (PERK, ATF6 and IRE1) involved in the UPR, PERK is thought to be activated very early in the response, and via phosphorylation of eIF2a, this rapidly reduces general protein synthesis and folding load of the cell (39), but allows the preferential translation of transcription factor, ATF4. Activation of ATF6 results in increased transcription of Xbp1, the mRNA of which is spliced by the activated form of Ire1 to produce a potent transcription factor Xbp1s, which activates genes in the proteasome degradation pathway (40, 41) . Mice with deficient Atf4 and Perk developed osteopenia phenotypes caused by impaired osteoblast differentiation (42, 43) . Oasis-deficient mice also exhibited severe osteopenia with decreased collagen I production and osteoblast activity (44) . Xbp1 has been shown to be essential for osteoblast differentiation through promoting transcription of Osterix (45) . Most relevant to 13del-tg mice may be Atf4. It has a broad effect on osteoblasts, bone metabolism and formation. It is activated via phosphorylation by RSK2 (46) . ATF4 can transactivate osteoblastrelated genes such as collagen I and other matrix proteins (osteocalcin and bone sialoprotein), thereby promoting bone synthesis and mineralization (47, 48) . It also enhances the uptake of amino acids, promoting protein synthesis (47, 48) . Atf4-deficient mice have low bone mass due to reduced osteoblast function (43) . In 13del-tg mice, upregulating ATF4 in osteocytes would maintain effective osteogenic activity. Thus, it is possible that maturation of osteocyte differentiation is suppressed in part by ATF4.
Therapeutic treatments of diseases affected by ER stress have been considered, and targeting a specific component or pathway in the UPR is one strategy (49) . However, if more than one sensor of the UPR is activated, it is not easy to identify the key player(s) responsible for the physiological changes. Global alleviation of ER stress is an alternative to assist cells to resume their normal function. Chemical chaperones are small molecules that help to alleviate ER stress by stabilizing protein conformation, improving ER folding capacity and facilitating trafficking of mutant proteins (50) . They have already shown therapeutic potential. 4-PBA is one of the chemical chaperones approved to treat urea cycle disorders (51) . It has been shown to reduce ER stress and restore glucose homeostasis in mice with type 2 diabetes (29) and to improve glucose tolerance in patients with insulin-resistance (52) . It also reversed severe leptin resistance in obese mice (51) , reduced ER stress in hepatocellular injury in mice (31) , and protected against cerebral and spinal cord ischemia in rabbit through inhibition of ER stress-mediated apoptosis and inflammation (53) . There is one report assessing the potential of 4-PBA for the treatment of skeletal disorders in mouse models with multiple epiphyseal dysplasia and MCDS that showed little or no effect on the growth plate changes (37) . The reason is unknown, but likely due to the avascular nature of cartilage limiting accessibility of the drug. 13del-tg mice have a growth plate defect as they carry an MCDS mutation in Col10a1, and we also did not observe any beneficial effect of 4-PBA on chondrocyte differentiation (data not shown). In bone, osteocytes are connected to the surface of the blood vessels through the canaliculi (35) , enabling access of 4-PBA.
In summary, our findings provided insights into the response of osteocytes to ER stress, and a better understanding of how this affects bone formation, particularly in hyperostosis. Importantly, we demonstrate the potential of chemical chaperones as therapeutic agent in a skeletal dysplasia.
Materials and Methods
Generation of transgenic mice
The generation of 13del-tg transgenic mice was described previously (24) . In brief, thirteen nucleotides were deleted from exon 3 of a 10. generated by pronuclear injection into one-cell CBA/C57BL6 F1-hybrid zygotes and specific lines were established from the founders (Supplementary Material, Fig. S1 ). FColX-tg mice were generated using the same Col10a1 DNA construct with a FLAG sequence inserted in frame within exon 2 (Supplementary Material, Fig. S3E ). 13del-MCDS mice were generated by homologous recombination in mouse embryonic stem cells (Supplementary Material, Fig. S3B ). The targeting construct carried the same 13 bp deletion as in the Col10a1-13del transgene. 13del-SP-tg mice were generated using the 10.5 kb Col10a1- (D) Diagrammatic representation of the osteoblast and osteocyte relationship in normal bone, the changed balance in 13del-tg mice due to activation of ER stress in osteocytes, and the proposed mechanism for mutations in the signal peptide of SOST in patients with CDD with activation of ER stress in osteocytes from the accumulation of mutant SOST proteins in the ER causing a high bone mass phenotype.
13del transgene, but with 0.9 kb of the promoter region deleted from the 5 0 end (Supplementary Material, Fig. S3D ).
Radiographical and microCT analyses of mouse skeleton
Mice were anesthetized for radiography using the Senograph 600T Senix HF X-ray machine (General Electric). MicroCT imagining was performed on euthanized mice using the Skyscan 1076 scanner (Bruker) at a resolution of 34.5 lm voxel size. Three-dimensional reconstruction was performed using CTVol, and images analyzed with the CTAn software. Bone mineralization density was calibrated with two standard phantoms (0.25 and 0.75 mg/cm 3 ) before calculation. The analyses on cortical bone in the middle diaphysis were performed on 29 slices (1 mm). The cortical thickness was calculated according to the previous description (54) . The thickness of the skull was measured at 4 different points in the middle of sagittal sections in each mouse head using the average for the final calculation.
Quantitative backscattered electron-scanning electron microscopy (QBSE-SEM)
Bone mineral density was quantitated by QBSE-SEM. Samples were fixed in 70% (v/v) ethanol, dehydrated with ethanol and embedded in polymethylmethacrylate (PMMA) (55) . The block is diamond-micromilled and carbon-coated. Images were taken with digital SEM (Zeiss DSM 962) equipped with an annular solid state BSE detector at 20 kV and 0.5 nA.
Histological and immunohistological analyses
Bones were fixed in 4% (v/v) paraformaldehyde, and if necessary, demineralized in 0.5 M EDTA (pH 8.0) containing 0.2% (v/v) formaldehyde prior to embedding in paraffin. Immunohistochemistry was performed using antibodies specific for CHOP, ATF3 and ATF4 (Santa Cruz Biotechnology), BiP (Stressgen), XBP1s (BioLegend, San Diego, California, United States), DMP1 (Thermo Fisher Scientific) and the 13del mutant collagen X (a specific antibody that recognizes mutant but not wildtype collagen X, described in (24) ). Signals were detected using the Alexa 488 conjugated secondary antibodies for 13del and BiP. For XBP1s antibody, the signal was further amplified with biotinylated tyramide (Perkin Elmer). For the detection of ATF4, ATF3 and XBP1s, sections were subjected to microwave antigen retrieval in Dako Target retrieval solution.
Staining for cortical bone canaliculi structures
Bone canaliculi were stained using the Bodian method (56) with some modifications. In brief, de-paraffinized bone sections were stained with protein-silver solution containing copper shots at 37 C for 20 h, and reduced in 1% (v/v) hydroquinone for 15 min.
The sections were then treated with a 0.2% (w/v) gold chloride solution for 30 min, and a 0.5% (v/v) oxalic acid solution for 20 min. Finally, they were treated in a 5% (w/v) sodium thiosulfate solution for 5 min before dehydration and embedded for imaging.
In-situ hybridization
In-situ hybridization was performed as previously described (24), using [ 35 S]UTP-labeled ribopobes for Runx2, Opn, Col1a1, Ocn and Sost. Probes for Col10a1, Col10a1-13del and BiP were described previously (24) .
Cell culture and DNA transfection
The human SOST cDNA was generated from genomic DNA by PCR using flanking primers 5 0 -tttatgcagctcccactggccctgtg-3 0 and 5 0 -aaactagtaggcgttctccagctcggcc-3 0 ; and overlapping primers 5 0 -cggcagctgtactcggacacgtctttggtctcaaaggggtggtg-3 0 and 5 0 -caccacc cctttgagaccaaagacgtgtccgagtacagctgccg-3 0 , with the amplicon cloned into pBluescript. The c.61G>T (p.Val21Leu) mutation is SOST was then introduced by site directed mutagenesis using primers 5 0 -cttccgtgtattggagggccag-3 0 and 5 0 -ctggccctccaatacacggaag-3 0 (underlined nucleotides denote the mutation). All constructs were validated by DNA sequencing. WT-SOST and Mut-SOST cDNA fragments were released and cloned into the pCAGGS expression vector. For in vitro expression, MC3T3-E1 cells were cultured in a-MEM supplemented with 10% fetal bovine serum in 6-well plates to around 70% confluency prior to transfection using Lipofectamine 2000 (Invitrogen). 2 lg of pCAGGS-WT-SOST and pCAGGS-Mut-SOST plasmid DNA were used in each transfection, and cells were collected 24 h later and total RNA prepared using the Trizol reagent (Invitrogen) according to the manufacturer's instructions.
Real time quantitative PCR
Reverse transcription of mRNA was performed using SuperScript II and random hexamer (Invitrogen). Real time quantitative PCR was performed using LightCyclerR 480 SYBER Green I Master kit (Roche). Primers used for qPCR are listed in Supplementary Material, Table S3 .
Microarray gene expression analysis
Parietal bones were dissected from three wt and three 13del-tg mice at postnatal day 10 and embedded in OCT compound and 5 mm cryo-sections were prepared for total RNA extraction using the Trizol Reagent (Invitrogen). RNA quality and integrity were assessed using RNA 6000 Nano Kit (Agilent). One microgram of RNA was used to generate antisense RNA using MessageAmp TM II-Biotin Enhanced Kit for hybridization to the Mouse Genome 430 2.0 GeneChip (Affymetrix) performed at the Center for Genomic Science of The University of Hong Kong. Data were normalized and analyzed using the geWorkbench platform (28) and DAVID (the database for annotation, visualization and integrated discovery) knowledgebase (57) . The minimum gene expression cutoff value was set at 100. Original microarray data is available at Gene Expression Omnibus (GEO) (GSE102588).
Administration of 4-phenylbutyric acid to mice
The chemical chaperone, sodium 4-phenylbutyric acid (4-PBA), was administered to mice at 1 mg/g of body weight per day by oral gavage as previously described (29) . In the first set of experiments, postnatal day 2 (P2) 13del-tg and wt mice were treated with 4-PBA or PBS (n ¼ 3 for each group) for five consecutive days and sacrificed at P7. In a second set, postnatal day 5 (P5) mice were treated with 4-PBA for ten consecutive days and sacrificed at postnatal day 15 (P15). Bones were fixed in 4% (v/v) paraformaldehyde for histological analyses.
